New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
07:44 EDTBMRNBioMarin survey shows strong Vimizim demand, says Leerink
Leerink said its survey of 14 physicians indicates "robust" demand and early commercial adoption of BioMarin's Vimizim. The firm believes physicians and patients are less critical of Vimizim's clinical profile than Wall Street. It reiterates an Outperform rating on BioMarin shares with a $90 price target.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
07:53 EDTBMRNLeerink to hold a tour
Subscribe for More Information
November 10, 2014
10:04 EDTBMRNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:02 EDTBMRNBioMarin upgraded to Buy from Neutral at Goldman
Goldman upgraded BioMarin to Buy based on increased confidence in BMN-111 for achondroplasia with expected proof-of-concept data in Q2 2015. The firm now sees a greater than 50% probability of success and peak sales of $900M. Price target raised to $104 from $78.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use